4th ISIRV Antiviral Group Conference
University of TexasAustin, USA Visit the Venue to read more
Except for influenza, no antiviral therapies are currently approved for common or novel respiratory viral infections.
Resistance to the licensed anti-M2 and anti-NA antivirals poses a serious limitation to the options for therapeutic interventions against influenza.
There is therefore urgent need for novel therapies directed against other influenza virus targets or which modulate host factors and the immune response, to mitigate the pathogenic consequences of infection.
Similarly, effective therapeutics are needed for other seasonal respiratory viruses, like RSV and rhinoviruses, and for emergent viruses like MERS-CoV and EV-D68.
This theme is reflected in the WHO’s “Battle Against Respiratory Viruses” (BRAVE) initiative and in a RFA-A1-14-026 from NIAID “Development of novel therapeutics for select agents”.
The meeting will focus on the pre-clinical and clinical development of novel antivirals and therapeutics against influenza and other respiratory viruses, from discovery to licensure. The objective is to bring together those working in these areas to review current activity and progress.
The programme will include sessions on:
Novel influenza targets: polymerase, nucleoprotein and NS1 inhibitors
New inhibitors of influenza NA and M2
Inhibitors of HA function: DAS-181; fusion inhibitors; broad spectrum MAbs and smaller molecules targeting the HA stem
Antivirals and antibody-based therapies against other seasonal and emerging respiratory viruses
Host cell targets and determinants of host susceptibility: factors involved in virus replication or mediating the inflammatory response
Clinical endpoints and regulatory issues
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
AT&T Hotel & Conference Center at the University of Texas
1900 University Avenue,
Austin, TX 78705
Reservations: Tel: + 512 404 3600
The organisers invite abstracts for oral or poster presentations in the following areas~
•New Inhibitors of Influenza Neuraminidase and M2 Protein Activities
•Inhibitors of Viral Polymerases, Nucleoproteins, or Accessory Proteins
•Inhibitors of Virion Attachment/Fusion Proteins
•Inhibitors of Other Respiratory Viruses - Both Seasonal and Emerging
•Host Cell Targets: Factors Involved in Virus Replication or Mediating the Inflammatory Response
•Human Challenge Models
•Regulatory Issues and Endpoint Selection